NCT01072695View on ClinicalTrials.gov

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

January 31, 2012

Conditions
HCV Infection
Interventions
DRUG

GS-9256

75 mg BID x 28 days

DRUG

GS-9190

40 mg BID x 28 days

DRUG

Ribavirin

1000-1200 mg/day given BID

DRUG

Peginterferon alfa-2a

180 ug q week

Trial Locations (12)

1070

Brussels

1200

Brussels

20099

Hamburg

30625

Hanover

38700

La Tronche

40237

Düsseldorf

60590

Frankfurt

75475

Paris

92110

Clichy

97080

Würzburg

E1 2AT

London

SE5 9RS

London

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY